Quarterly ResultMay 5, 2026, 07:33 AM
Compass Therapeutics: Tovecimig BLA Planned; Q1 Net Loss $18.3M
AI Summary
Compass Therapeutics reported a Q1 2026 net loss of $18.3 million and provided a corporate update. The company announced positive Phase 2/3 data for tovecimig in biliary tract cancer, including statistically significant improvement in progression-free survival and signals of a survival benefit, and plans to submit a Biologics License Application (BLA) later this year. Additionally, the Phase 1 study for CTX-8371 will be presented at ASCO 2026, and initial data for CTX-10726 is expected in Q4 2026. The company holds $195 million in cash, expected to fund operations into 2028.
Key Highlights
- Tovecimig Phase 2/3 study showed 17.1% ORR vs 5.3% for paclitaxel (p=0.031).
- Tovecimig demonstrated 4.7 months PFS vs 2.6 months for paclitaxel (HR=0.44, p<0.0001).
- Tovecimig received Orphan Drug Designation; BLA submission planned later this year.
- CTX-8371 Phase 1 data selected for ASCO 2026 presentation; cohort expansions initiated.
- CTX-10726 Phase 1 study initiated, with initial data expected in Q4 2026.
- Q1 2026 net loss was $18.3 million, or $0.10 per common share.
- Cash and marketable securities totaled $195 million as of March 31, 2026, funding operations into 2028.
- R&D expenses increased 3% to $13.4 million; G&A expenses increased 41% to $6.9 million.